HTG Molecular Diagnostics (OTCPK:HTGM.Q) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

HTGM.Q 주식 개요

생명과학 회사인 HTG 분자 진단은 정밀 의학에 중점을 두고 있습니다.

HTGM.Q 기본 분석
눈송이 점수
가치 평가	2/6
미래 성장	0/6
과거 실적	0/6
재무 상태	2/6
배당금	0/6

보상

위험 분석

주식은 유동성이 매우 낮습니다

의미 있는 시가총액이 없습니다. ( $6K )

지난 1년간 수익이 28.2% 감소했습니다.

최신 재무 보고서는 1년이 넘었습니다.

HTG Molecular Diagnostics, Inc. 경쟁사

SOAFEE

OTCPK:SOFE

US$112.8k

Pear Therapeutics

OTCPK:PEAR.Q

US$142.0

MediXall Group

OTCPK:MDXL

US$138.0

InnovaQor

OTCPK:INQR

US$878.3k

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 HTG Molecular Diagnostics
과거 주가
현재 주가	US$0.0015
52주 최고치	US$0.66
52주 최저치	US$0.0013
베타	2.7
11개월 변경	-40.00%
3개월 변경 사항	n/a
1년 변경 사항	-99.59%
33년 변화	-100.00%
5년 변화	-100.00%
IPO 이후 변화	-100.00%

최근 뉴스 및 업데이트

Recent updates

These Analysts Think HTG Molecular Diagnostics, Inc.'s (NASDAQ:HTGM) Sales Are Under Threat

Mar 26

What Type Of Returns Would HTG Molecular Diagnostics'(NASDAQ:HTGM) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Jan 20

HTG shares surge after upbeat 2020 revenue forecast

Jan 05

HTG Molecular Diagnostics announced 1:15 reverse stock split

Nov 23

HTG Molecular Diagnostics (HTGM) Investor Presentation - Slideshow

Nov 18

주주 수익률

	HTGM.Q	US Healthcare Services	US 마켓
7D	-40.0%	-3.3%	0.4%
1Y	-99.6%	-20.3%	22.9%

수익률 대 산업: HTGM.Q 지난 1년 동안 -21.4 %를 반환한 US Healthcare Services 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: HTGM.Q 지난 1년 동안 23.3 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is HTGM.Q's price volatile compared to industry and market?
HTGM.Q volatility
HTGM.Q Average Weekly Movement	n/a
Healthcare Services Industry Average Movement	9.3%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.5%
10% least volatile stocks in US Market	2.9%

안정적인 주가: HTGM.Q 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: 지난 1년간 HTGM.Q 의 변동성 변화를 확인하기에는 데이터가 충분하지 않습니다.

회사 소개

설립	직원	CEO	웹사이트
1997	54	John Lubniewski	www.htgmolecular.com

생명과학 회사인 HTG 분자 진단은 정밀 의학에 중점을 두고 있습니다. 이 회사는 샘플 처리를 자동화하고 다양한 분자 표적을 프로파일링하는 기기, 소모품, 소프트웨어를 제공합니다. 판매되는 분자 프로파일링 패널로는 HTG 전사체 패널, HTG EdgeSeq 정밀 면역 종양학 패널, HTG EdgeSeq miRNA 전체 전사체 분석, HTG EdgeSeq DLBCL 세포 기원 분석 EU, HTG EdgeSeq 종양학 바이오마커 패널, HTG 면역 반응 패널 및 HTG 마우스 mRNA 종양 반응 패널 등이 있습니다.

HTG Molecular Diagnostics, Inc. 기본 사항 요약

HTG Molecular Diagnostics 의 수익과 매출은 시가총액과 어떻게 비교하나요?
HTGM.Q 기본 통계
시가총액	US$3.32k
수익(TTM)	-US$20.15m
수익(TTM)	US$6.21m

0.0x

P/S 비율

0.0x

P/E 비율

HTGM.Q 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
HTGM.Q 손익 계산서(TTM)
수익	US$6.21m
수익 비용	US$11.13m
총 이익	-US$4.92m
기타 비용	US$15.23m
수익	-US$20.15m

최근 보고된 수익

Mar 31, 2023

다음 수익 날짜

n/a

주당 순이익(EPS)	-9.10
총 마진	-79.14%
순이익 마진	-324.28%
부채/자본 비율	1,452.4%

HTGM.Q 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

HTGM.Q 주식 개요

보상

위험 분석

HTG Molecular Diagnostics, Inc. 경쟁사

OTCPK:SOFE

US$112.8k

OTCPK:PEAR.Q

US$142.0

OTCPK:MDXL

US$138.0

OTCPK:INQR

US$878.3k

가격 내역 및 성능

최근 뉴스 및 업데이트

Nasdaq to Delist the Common Stock of HTG Molecular Diagnostics

HTG Molecular Diagnostics, Inc.(OTCPK:HTGM.Q) dropped from NASDAQ Composite Index

HTG Molecular Diagnostics, Inc.(NasdaqCM:HTGM) dropped from S&P TMI Index

Htg Molecular Diagnostics, Inc. Announces Termination of Employment of Byron T. Lawson as Senior Vice President and Chief Commercial Officer

HTG Molecular Diagnostics, Inc. Filed for Bankruptcy

HTG Molecular Diagnostics Receives Non-Compliance Notice From Nasdaq

Recent updates

Nasdaq to Delist the Common Stock of HTG Molecular Diagnostics

HTG Molecular Diagnostics, Inc.(OTCPK:HTGM.Q) dropped from NASDAQ Composite Index

HTG Molecular Diagnostics, Inc.(NasdaqCM:HTGM) dropped from S&P TMI Index

Htg Molecular Diagnostics, Inc. Announces Termination of Employment of Byron T. Lawson as Senior Vice President and Chief Commercial Officer

HTG Molecular Diagnostics, Inc. Filed for Bankruptcy

HTG Molecular Diagnostics Receives Non-Compliance Notice From Nasdaq

HTG Molecular Diagnostics, Inc. to Highlight the Advantages of its Drug Discovery Engine at the 2023 Biotechnology Innovation Organization

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings: EPS misses analyst expectations

Consensus forecasts updated

HTG Molecular Diagnostics, Inc. Provides a Year-End Update on its Drug Discovery Business and Attends LifeSci Partners 2023 Corporate Access Event

HTG Molecular Diagnostics, Inc. Provides Revenue Guidance for Full Year 2022

HTG Molecular Diagnostics, Inc. has completed a Follow-on Equity Offering.

HTG Molecular Diagnostics, Inc. Receives Non-Compliance Notice From Nasdaq

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

HTG Molecular Diagnostics, Inc. announced that it has received $0.0001 million in funding

HTG Molecular Diagnostics Receives Non-Compliance Letter from Nasdaq

Consensus forecasts updated

HTG Molecular Diagnostics, Inc. Announces Board Changes

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

HTG Molecular Q2 GAAP loss per share widens, revenue down

HTG Molecular Diagnostics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Price target decreased to US$3.25

HTG Molecular Diagnostics amends senior loan facility

HTG Molecular Diagnostics, Inc., Annual General Meeting, Aug 17, 2022

HTG Molecular Diagnostics, Inc. Releases Second Whitepaper for Its Transcriptome-Informed Approach to Drug Discovery

HTG Molecular Diagnostics Receives Non-Compliance Letter from Nasdaq

Consensus forecasts updated

HTG Molecular Diagnostics, Inc. Provides Revenue Guidance for the Full Year 2022

First quarter 2022 earnings: EPS and revenues miss analyst expectations

HTG Molecular Diagnostics, Inc. to Report Q1, 2022 Results on May 12, 2022

Price target decreased to US$9.50

HTG Molecular Diagnostics, Inc. Expands Features of Proprietary HTG EdgeSeq Technology

Consensus revenue estimates fall by 16%

Full year 2021 earnings: EPS exceeds analyst expectations

HTG Molecular Diagnostics, Inc. Appoints Dr. Robert Spitale to Therapeutics Scientific Advisory Board

HTG Molecular Diagnostics, Inc. Appoints Christopher P. Kiritsy to Serve as Class I Director, Member of Audit Committee

HTG Molecular Diagnostics, Inc. Provides Revenue Guidance for the Full Year 2021

HTG Molecular Diagnostics, Inc. Completes HTP Product Next-Phase Development Milestone

Is HTG Molecular Diagnostics (NASDAQ:HTGM) Using Debt In A Risky Way?

Third quarter 2021 earnings released: US$0.60 loss per share (vs US$1.12 loss in 3Q 2020)

Is HTG Molecular Diagnostics (NASDAQ:HTGM) Weighed On By Its Debt Load?

Consensus forecasts updated

Second quarter 2021 earnings released: US$0.39 loss per share (vs US$1.30 loss in 2Q 2020)

HTG Molecular Diagnostics, Inc. Announces Commercial Launch and Immediate Availability of its HTG Transcriptome Panel

HTG Molecular Diagnostics, Inc. Announces Completion of Product Design Lock for the HTG Transcriptome Panel

HTG Molecular completes product design lock for planned transcriptome panel

First quarter 2021 earnings released: US$0.64 loss per share (vs US$1.27 loss in 1Q 2020)

Price target decreased to US$9.75

HTG Molecular Diagnostics, Inc. Reports Preliminary Financial Results for the First Quarter Ended March 31, 2021 and Full Year 2021

Full year 2020 earnings released: US$4.51 loss per share (vs US$7.60 loss in FY 2019)

Consensus forecasts updated

Price target decreased to US$11.75

These Analysts Think HTG Molecular Diagnostics, Inc.'s (NASDAQ:HTGM) Sales Are Under Threat

HTG Molecular Diagnostics, Inc. to Report Fiscal Year 2020 Results on Mar 25, 2021

HTG Concludes Feasibility Testing & Releases Second White Paper for its Planned Whole Transcriptome Panel Using HTG EdgeSeq Technology

New 90-day high: US$7.83